Immunoglobulin Or Antibody Binds A Specifically Identified Amino Acid Sequence Patents (Class 435/331)
-
Publication number: 20130323254Abstract: Provided are specific antibodies against T-cell immune response cDNA7 (TIRC7) costimulatory molecule, which are capable of inhibiting proliferation of peripheral blood mononuclear cells (PBMCs). In particular, high affinity monoclonal and chimeric anti-TIRC7 antibodies are described. Compositions comprising such antibodies and their use for the treatment of immune diseases are provided.Type: ApplicationFiled: December 21, 2012Publication date: December 5, 2013Inventor: Nalan Utku
-
Publication number: 20130315917Abstract: Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human ?-amyloid peptide as compare to low molecular weight forms of ?-amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment of Alzheimer's disease by effectively blocking the ability of the protofibril form of ?-amyloid peptide to form fibril forms linked with complications associated with Alzheimer's disease. The isolated antibodies of the present invention are also useful in various diagnostic assays and associated kits.Type: ApplicationFiled: May 28, 2013Publication date: November 28, 2013Applicant: ROCKEFELLER UNIVERSITY (THE)Inventor: ROCKEFELLER UNIVERSITY (THE)
-
Publication number: 20130316378Abstract: The invention provides methods for predicting, diagnosing or monitoring acute cardiac disorders, cardiac transplant rejection, or distinguishing acute cardiac disorders from pulmonary disorders, by measuring BNP signal peptide levels in a sample taken from a subject shortly after onset of, or presentation with the disorder or transplant rejection.Type: ApplicationFiled: April 15, 2013Publication date: November 28, 2013Applicant: OTAGO INNOVATION LIMITEDInventors: Christopher Joseph PEMBERTON, Arthur Mark RICHARDS, Michael Gary NICHOLLS, Timothy Grant YANDLE
-
Publication number: 20130315918Abstract: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications.Type: ApplicationFiled: June 27, 2013Publication date: November 28, 2013Applicant: Genentech, Inc.Inventors: GERMAINE FUH, HANS-PETER GERBER, WEI-CHING LIANG, FREDERIC FELLOUSE, SACHDEV S. SIDHU, CHRISTIAN WIESMANN
-
Publication number: 20130315915Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: ApplicationFiled: April 30, 2013Publication date: November 28, 2013Applicant: Celera CorporationInventors: Steve RUBEN, Tao HE, Candy LEE, Karen VAN ORDEN, Paul MOORE
-
Patent number: 8591863Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: GrantFiled: June 20, 2012Date of Patent: November 26, 2013Assignee: Abbvie Biotherapeutics Inc.Inventors: Debbie Law, Kurt Gish
-
Publication number: 20130309694Abstract: The present invention provides a hybridoma cell line (DSM ACC3145), wherein the hybridoma cell line produces an antibody which specifically binds to an amino acid sequence of type II collagen comprising: K-G-E-P-G-D-D-G-P-S-C (as set forth in SEQ ID NO. 1); and a method for detecting osteoarthritis, by identifying a presence of type II collagen in a urine sample through containing the urine sample with the said antibody.Type: ApplicationFiled: July 30, 2012Publication date: November 21, 2013Inventors: Chih-Hsin HUNG, Chi-Yen Shen, Shyh-Ming Kuo, I-Fen Chen, Shih-Han Wang
-
Patent number: 8586037Abstract: The invention provides the antibody D9.2 and antibody molecules based on D9.2 which bind interleukin-17 receptor B. These may be useful in therapy, e.g. the treatment of asthma, ulcerative colitis or Crohn's disease.Type: GrantFiled: March 31, 2010Date of Patent: November 19, 2013Assignee: Medical Research CouncilInventors: Andrew Neil James McKenzie, Daniel Neill
-
Publication number: 20130303598Abstract: This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling, variants and derivatives of the polynucleotides and corresponding polypeptides, uses of the polynucleotides, polypeptides, variants and derivatives, and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders. Disclosed in particular are the isolation and identification of polynucleotides polypeptides variants and derivatives involved in osteoclast activity, validation of the identified polynucleotides for their potential as therapeutic targets and use of the polynucleotides, polypeptides, variants and derivatives for the amelioration of disease states and research purposes.Type: ApplicationFiled: July 25, 2013Publication date: November 14, 2013Inventors: Roy Rabindranauth SOOKNANAN, Gilles Bernard TREMBLAY, Mario FILION
-
Publication number: 20130295103Abstract: The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.Type: ApplicationFiled: March 11, 2013Publication date: November 7, 2013Applicant: BIONOVION HOLDING B.V.Inventors: Jan Paul Medema, Hans Van Eenennaam, Marco Guadagnoli, Fiona Clare Kimberley, Uyen Truong Phan
-
Publication number: 20130295021Abstract: Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: October 11, 2011Publication date: November 7, 2013Inventors: Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Roger Nitsch, Christoph Hock
-
Publication number: 20130295125Abstract: Methods and compositions for detecting MusPV, also known as MmuPv1, infection of a rodent subject are described according to aspects of the present invention. In specific aspects, the present invention relates to assays for detecting MusPV infection of a rodent subject; vaccine compositions for inducing an immunological response against MusPV in a rodent subject; methods of inducing an immunological response to MusPV in a rodent subject; isolated MusPV protein; isolated antibodies which specifically binds to an MusPV protein, a fragment or variant thereof; isolated recombinantly expressed MusPV proteins; expression constructs comprising a nucleic acid encoding an MusPV protein; host cells comprising the expression construct; and hybridoma cell lines expressing an anti-MusPV monoclonal antibody specific for MusPV.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Applicants: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, THE JACKSON LABORATORYInventors: John P. Sundberg, Joongho Joh, A. Bennett Jenson, Shin-Je Ghim
-
Publication number: 20130295105Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.Type: ApplicationFiled: March 13, 2013Publication date: November 7, 2013Inventors: Austin L. GURNEY, Aaron Ken Sato, Fumiko Takada Axelrod, Timothy Charles Hoey, Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra
-
Patent number: 8575316Abstract: Provided is a pharmaceutical composition for treating and/or preventing abnormal bone metabolism targeting a protein encoded by a gene strongly expressed in osteoclasts. Specifically provided is a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation, and the like.Type: GrantFiled: April 7, 2010Date of Patent: November 5, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Yoshiharu Hiruma, Eisuke Tsuda, Takeshi Takizawa, Makiko Nakayama
-
Publication number: 20130291136Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.Type: ApplicationFiled: March 13, 2013Publication date: October 31, 2013Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
-
Publication number: 20130287783Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.Type: ApplicationFiled: April 27, 2013Publication date: October 31, 2013Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Helen Alison Frank, Alice A. McDonald, Theresa L. O'Keefe
-
Publication number: 20130287782Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from E. faecalis, methods for isolating such antigens and specific uses thereof.Type: ApplicationFiled: March 28, 2013Publication date: October 31, 2013Inventors: ANDREAS MEINKE, ESZTER NAGY, MARKUS HANNER, DIETER GELBMANN
-
Patent number: 8563271Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.Type: GrantFiled: August 22, 2012Date of Patent: October 22, 2013Assignee: UCB Manufacturing, Inc.Inventors: David G. Winkler, Jiye Shi, John Latham
-
Publication number: 20130272968Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: October 17, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder, Andrea Eicker, Andreas Wilmen
-
Publication number: 20130266573Abstract: The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.Type: ApplicationFiled: December 11, 2012Publication date: October 10, 2013Applicant: ABBVIE INC.Inventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Gerd Ritter, Achim Jungbluth, Elisabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice
-
Publication number: 20130266574Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: ApplicationFiled: December 12, 2012Publication date: October 10, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Mark W. SLEEMAN, Viktoria GUSAROVA, Jee H. KIM, Gang CHEN
-
Publication number: 20130260455Abstract: The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.Type: ApplicationFiled: March 1, 2013Publication date: October 3, 2013Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Austin L. GURNEY, Timothy Charles Hoey, Edward Thein Htun van der Horst, Aaron Ken Sato, Yuan Ching Liu, Maureen Fitch Bruhns, John A. Lewicki
-
Publication number: 20130260388Abstract: The present invention provides uses of cytokeratins as markers for diagnosing epithelium derived cancers. The present invention provides caner-related epitopes of cytokeratins and monoclonal antibodies which specifically recognize the epitopes. The present invention also provides methods for the early screen, diagnosis or prognosis of epithelium derived cancers in subjects, methods for the evaluation of therapeutic effect of related medicaments or therapies, and kits for accomplishing the methods.Type: ApplicationFiled: September 9, 2010Publication date: October 3, 2013Inventors: Enyun Shen, Yang Song, Shiqi Ren
-
Publication number: 20130252326Abstract: Novel anti-cancer agents, including, but not limited to, antibodies, that bind to human frizzled receptors are provided. Novel epitopes within the human frizzled receptors which are suitable as targets for anti-cancer agents are also identified. Methods of using the agents or antibodies, such as methods of using the agents or antibodies to inhibit Wnt signaling and/or inhibit tumor growth are further provided.Type: ApplicationFiled: March 13, 2013Publication date: September 26, 2013Applicant: ONCOMED PHARMACEUTICALS, INC.Inventors: AUSTIN L. GURNEY, AARON KEN SATO, FUMIKO TAKADA AXELROD, TIMOTHY CHARLES HOEY, SANJEEV H. SATYAL, SATYAJIT SUJIT KUMAR MITRA
-
Publication number: 20130251721Abstract: The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.Type: ApplicationFiled: December 20, 2012Publication date: September 26, 2013Applicant: NOVO NORDISK A/SInventors: Ida Hilden, Berit Olsen Krogh, Jes Thorn Clausen, Ole Hvilsted Olsen, Jens Breinholt, Brian Lauritzen, Brit Binow Soerensen
-
Publication number: 20130251723Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor ROR1. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including non-small cell lung carcinoma, B-cell chronic lymphocytic leukemia and colon cancer.Type: ApplicationFiled: October 3, 2011Publication date: September 26, 2013Applicant: OXFORD BIOTHERAPEUTICS LTD.Inventors: Christian Rohlff, Alasdair Stamps, Jonathan Alexander Terrett
-
Publication number: 20130243753Abstract: The invention provides anti-Axl antibodies and methods of using the same.Type: ApplicationFiled: December 7, 2012Publication date: September 19, 2013Applicant: GENENTECH, INC.Inventors: Lin Pei, Yan Wu, Xiaofen Ye
-
Publication number: 20130243780Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: ApplicationFiled: September 17, 2012Publication date: September 19, 2013Applicant: THE UAB RESEARCH FOUNDATIONInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman
-
Publication number: 20130243779Abstract: The present invention relates to a protective peptide of Enterococcus faecalis (E. faecalis) or a functional active variant thereof, optionally further consisting of additional amino acid residue(s); a nucleic acid coding for the same; a pharmaceutical composition comprising said peptide or said nucleic acid; an antibody or functional active fragment thereof specifically binding to the antigen; a hybridoma cell line which produces said antibody; a method for producing said antibody; a pharmaceutical composition comprising said antibody; the use of said peptide or said nucleic acid for the manufacture of a medicament for the immunization or treatment of a subject; the use of said antibody or functional fragment thereof for the manufacture of a medicament for the treatment of an infection; a method of diagnosing an E. faecalis infection; and the use of said peptide for the isolation and/or purification and/or identification of an interaction partner of the peptide.Type: ApplicationFiled: February 4, 2010Publication date: September 19, 2013Applicant: Intercell AGInventors: Eszter Nagy, Beatrice Tschanun, Markus Hanner, Manfred Berger, Andreas Meinke, Alexander Von Gabain, Barbara Murray, Kavindra Singh
-
Publication number: 20130245232Abstract: It is an object of the present invention to provide an anti-cadherin antibody having high antibody-dependent cellular cytotoxicity. The present invention provides an anti-cadherin antibody, which recognizes any one of an upstream region of EC1, a cadherin domain 4 (EC4) and a cadherin domain 5 (EC5), wherein an antibody-dependent cellular cytotoxicity at an antibody concentration of 1 ?g/mL is 30% or more.Type: ApplicationFiled: May 3, 2013Publication date: September 19, 2013Applicants: PERSEUS PROTEOMICS INC., THE UNIVERSITY OF TOKYOInventors: Hiroyuki ABURATANI, Lilin ZHANG, Keisuke ISHII, Katsushi KOUDA, Aya SAKAMOTO, Keiko KATSUMI, Hiroshi ONISHI, Yoko KAYUKAWA
-
Publication number: 20130236467Abstract: The invention relates to combinations of HGF-antagonists with VEGF antagonists, and provides antigen-binding proteins which bind to HGF comprising a protein scaffold which are linked to one or more epitope-binding domains wherein the antigen-binding protein has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain, methods of making such constructs and uses thereof.Type: ApplicationFiled: November 23, 2011Publication date: September 12, 2013Inventors: Jeremy Griggs, Radha Shah Parmar, Michael Steward
-
Patent number: 8529902Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.Type: GrantFiled: October 17, 2003Date of Patent: September 10, 2013Assignee: Genmab A/SInventors: Jessica Teeling, Sigrid Ruuls, Martin Glennie, Jan G. J. van de Winkel, Paul Parren, Jørgen Petersen, Ole Baadsgaard, Haichun Huang
-
Publication number: 20130231466Abstract: The inventors discovered that the adhesion molecule CAR, known to be localized in intracellular adhesion sites, functioned as an adhesion molecule for activated lymphocytes. Further, the inventors identified CARL, a novel CAR ligand expressed in lymphocytes, and clarified that the ligand was expressed selectively in Th1 cells. In addition, they found that anti-CAR antibodies could inhibit the adhesion of activated lymphocytes to CAR molecules. Thus, the present invention provides methods for detecting Th1 cells using CAR or anti-CARL antibodies, and methods of screening for inhibitors suppressing the adhesion of Th1 cells using the binding between CAR and CARL as an index. Furthermore, the present invention relates to methods of screening for inhibitors of the binding between CAR and CARL, antibodies that inhibit the binding between CAR and CARL, and therapeutic compositions comprising these antibodies.Type: ApplicationFiled: March 15, 2013Publication date: September 5, 2013Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Keiko Yamaguchi, Toshio Imai, Kenzo Muramoto
-
Publication number: 20130231465Abstract: The present invention relates to an antibody binding to a carbonic anhydrase, wherein the antibody comprises (a) the amino acid sequences SEQ ID NOS. 1 (CDR 1), 2 (CDR 2) and 3 (CDR 3) determining the CDRs of the VH region, and the amino acid sequences SEQ ID NOS. 4 (CDR 1), 5 (CDR 2) and 6 (CDR 3) determining the CDRs of the VL region; or (b) the amino acids sequences of (a), wherein at least one amino acid is conservatively substituted in any one of the amino acid sequences SEQ ID NOS. 1 to 6.Type: ApplicationFiled: May 2, 2011Publication date: September 5, 2013Inventors: Reinhard Zeidler, Christina Battke, Elisabeth Flathey, Andrew Flathey, Claudiu Supuran
-
Publication number: 20130230869Abstract: The purpose of the present invention is to provide a novel monoclonal antibody which binds to SLC6A6 or an extracellular domain thereof. The present invention relates to a monoclonal antibody which recognizes native SLC6A6 or a polypeptide of an extracellular domain of SLC6A6.Type: ApplicationFiled: September 1, 2011Publication date: September 5, 2013Applicants: NATIONAL CANCER CENTER, BIO MATRIX RESEARCH, INC.Inventors: Hiroyuki Satofuka, Youko Okabe, Yasuhiro Matsumura, Masahiro Yasunaga
-
Publication number: 20130230526Abstract: The present invention relates to an isolated nucleic acid molecule encoding an antigen, a vector comprising such nucleic acid molecule and a host cell comprising such vector. Furthermore, the invention provides antigens from Klebsiella species, fragments and variants thereof, a process for producing such antigens, and a process for producing cells expressing such antigens. Moreover, the present invention provides antibodies binding to such antigen, hybridoma cells producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of inhibiting the interaction activity of such antigen, methods for diagnosis or for treatment or prevention of an infection.Type: ApplicationFiled: July 6, 2012Publication date: September 5, 2013Applicant: Intercell AGInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
-
Publication number: 20130224189Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.Type: ApplicationFiled: March 1, 2013Publication date: August 29, 2013Applicant: IMMUNEX CORPORATIONInventor: IMMUNEX CORPORATION
-
Publication number: 20130224854Abstract: A monoclonal antibody, wherein the monoclonal antibody specifically binds to a single-chain type IV collagen polypeptide, and wherein the monoclonal antibody is obtained by a hybridoma line of Anti NK-Antigen monoclonal antibody #141 having Accession No: FERM BP-11300.Type: ApplicationFiled: May 7, 2013Publication date: August 29, 2013Applicant: NIPPON KAYAKU KABUSHIKI KAISHAInventor: Nippon Kayaku Kabushiki Kaisha
-
Patent number: 8518871Abstract: The present disclosure provides peptides and peptide compositions, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (SC) and/or the cellular membranes of viable cells.Type: GrantFiled: October 5, 2011Date of Patent: August 27, 2013Assignee: The Regents of the University of CaliforniaInventors: Tracy Hsu, Samir M. Mitragotri
-
Publication number: 20130209455Abstract: The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: December 20, 2012Publication date: August 15, 2013Applicant: Roche Glycart AGInventor: Roche Glycart AG
-
Publication number: 20130209355Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: June 8, 2011Publication date: August 15, 2013Applicant: GENMAB A/SInventors: Michel De Weers, Tim Walseth, Jan Van De Winkel, Tom Vink, Paul Parren
-
Publication number: 20130202608Abstract: The present invention relates to the murine monoclonal antibody 4C2 or to chimeric or humanized monoclonal antibodies specific to a major neutralizing epitope of influenza H5 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using such murine or chimeric or humanized monoclonal antibodies or fragments thereof.Type: ApplicationFiled: August 23, 2010Publication date: August 8, 2013Applicant: TEMASEK LIFE SCIENCES LABORATORY LIMITEDInventors: Prabakaran Mookkan, Fang He, Hwei-Sing Jimmy Kwang
-
Publication number: 20130203079Abstract: The invention relates to antibodies that are capable to bind the extracellular domain of integrin. Another object of the invention concerns the use of said antibodies for detecting integrins in archival formalin fixed paraffin embedded (FFPE) tissue. The invention also relates to methods for preparing monoclonal rabbit antibodies, wherein the immunogen is an insect expression culture-derived recombinant extracellular integrin domain, and another method for screening anti-integrin antibodies that discriminate between closest integrin homologues and that are especially suited for immunohistochemistry in FFPE material.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNGInventor: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
-
Publication number: 20130202607Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: August 13, 2012Publication date: August 8, 2013Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Norihiko SHIRAISHI, Akiko FURUYA, Hiroe TOKI, Hiroshi ANDO, Masayo SUZUKI, Tsuguo KUBOTA
-
Patent number: 8501427Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.Type: GrantFiled: January 23, 2008Date of Patent: August 6, 2013Assignee: University College Cardiff Consultants LimitedInventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
-
Publication number: 20130196378Abstract: The present invention provides an anti-CD81 antibody usable as a pharmaceutical product for human. Specifically, the present invention provides an anti-human CD81 antibody capable of binding to a peptide region consisting of the amino acid sequence of the amino acid numbers 80 to 175 in the amino acid sequence shown in SEQ ID NO:22.Type: ApplicationFiled: March 15, 2013Publication date: August 1, 2013Applicant: DAINIPPON SUMITOMO PHARMA CO., LTD.Inventor: DAINIPPON SUMITOMO PHARMA CO., LTD.
-
Publication number: 20130195869Abstract: An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation.Type: ApplicationFiled: September 27, 2011Publication date: August 1, 2013Applicants: NB Health Laboratory Co., Ltd, Sekisui Chemical Co., Ltd.Inventors: Naoki Nishiguchi, Akiyoshi Hirayama, Masahiro Furutani, Tatsuo Shimizu, Kiyoshi Takayama, Tomoko Shimizu, Kazuya Suzuki
-
Publication number: 20130195881Abstract: Novel antibodies and their fragments are disclosed that specifically bind to CD4. Anti-CD4 antibodies are disclosed having amino acid substitutions in the hinge region that prevent intrachain disulfide bond formation resulting in antibody molecules with surprisingly improved bivalent stability. Increased stability facilitates manufacturing and provides increased in vivo stability. Antibodies are also disclosed that have amino acid substitutions that reduce binding to Fc receptor and ADCC activity that also result in a surprising effect on CD4 internalization. In addition, genes for such antibodies are disclosed that have been modified such that they have increased expression over their unmodified counterparts.Type: ApplicationFiled: April 28, 2008Publication date: August 1, 2013Inventors: Sanjaya Singh, Sek Chung Fung, Dan Huang
-
Publication number: 20130189269Abstract: The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.Type: ApplicationFiled: March 14, 2013Publication date: July 25, 2013Applicant: ACCELERON PHARMA, INC.Inventor: ACCELERON PHARMA, INC.
-
Patent number: 8491900Abstract: A novel signal transducer TAB2 which acts as an adapter molecule of TRAF6 and TAK1 and mediates the activation of TAK1 in the signal transduction of IL-1 was isolated. TAB2 induced the activation of NF-?B and JNK by IL-1. The signal transduction by IL-1 was inhibited by inhibiting the signal transduction of TAB2 with the use of a dominant negative mutant of TAB2. A compound inhibiting the signal transduction in TAB2 is useful as an anti-inflammatory drug.Type: GrantFiled: October 21, 2011Date of Patent: July 23, 2013Inventor: Kunihiro Matsumoto